The doxorubicin-streptozotocin combination for the treatment of advanced well-differentiated pancreatic endocrine carcinoma: a judicious option?
Due to their rarity, only few trials have studied the role of the doxorubicin-streptozotocin (DS) combination in advanced well-differentiated pancreatic endocrine carcinomas (AWDPEC). However, the published results are inconsistent. We reviewed all AWDPEC (5-year period, 45 patients) treated in our...
Gespeichert in:
| Veröffentlicht in: | European journal of cancer (1990) 2004-03, Vol.40 (4), p.515-520 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 520 |
|---|---|
| container_issue | 4 |
| container_start_page | 515 |
| container_title | European journal of cancer (1990) |
| container_volume | 40 |
| creator | Delaunoit, Th Ducreux, M. Boige, V. Dromain, C. Sabourin, J.-C. Duvillard, P. Schlumberger, M. de Baere, T. Rougier, P. Ruffie, P. Elias, D. Lasser, P. Baudin, E. |
| description | Due to their rarity, only few trials have studied the role of the doxorubicin-streptozotocin (DS) combination in advanced well-differentiated pancreatic endocrine carcinomas (AWDPEC). However, the published results are inconsistent. We reviewed all AWDPEC (5-year period, 45 patients) treated in our institution with the DS combination for: objective response rate (ORR), progression-free survival, overall survival (OS) and toxicity. An ORR of 36% (95% Confidence Interval (CI) 22–49) was obtained, with 16 partial responses (PR). The mean duration of PR was of 19.7 months. Two and 3-year OS rates were 50.2 and 24.4%, respectively. Toxicities were mainly digestive (grade ⩾3 vomiting, 13%) and haematological (grade ⩾3 neutropenia, 24%). Previous systemic chemotherapy and malignant hepatomegaly were associated with a poorer ORR (P=0.033, P=0.016) and OS (P=0.008, P=0.045). Multivariate analysis demonstrated previous chemotherapy as the only independent predictive-factor for survival (P=0.013). In conclusion, our data confirm the sensitivity of AWDPEC to the DS combination, with an ORR of 36% and a remarkable median response duration of 19.7 months, and suggests that it could be considered as a valid option in first-line therapy. |
| doi_str_mv | 10.1016/j.ejca.2003.09.035 |
| format | Article |
| fullrecord | <record><control><sourceid>elsevier_pubme</sourceid><recordid>TN_cdi_pubmed_primary_14962717</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0959804903009274</els_id><sourcerecordid>S0959804903009274</sourcerecordid><originalsourceid>FETCH-LOGICAL-e292t-196e14afe9086d0d23c9a072fe3d907f81c752bf1efb03cc62f0ed3537ae91a63</originalsourceid><addsrcrecordid>eNpFkctu1TAQhi1ERQ-FF2CBvGGZMLZzM0JCVcWlUiU2ZW1N7LFwdBJHjk9peQoeGUctYjWamU9z-X_G3gioBYju_VTTZLGWAKoGXYNqn7GDGHpdwdDK5-wAutXVAI0-Zy-3bQKAfmjgBTsXje5kL_oD-3P7k7iL9zGdxmDDUm050Zrj75hjSbmN8xgWzCEu3MfEc8ELgXmmJfPoObo7XCw5_ouOx8oF7ymVVsBcamtp7XCwnBYXbQoLcYupTI4zfuDIp5Mra-Np43Hdl3x6xc48Hjd6_RQv2I8vn2-vvlU3379eX13eVCS1zJXQHYkGPWkYOgdOKqsReulJOQ29H4TtWzl6QX4EZW0nPZBTreqRtMBOXbC3j3PX0ziTM2sKM6YH80-aArx7AnCzePSp_BK2_1zbFC1h5z4-clSuvQuUzGYD7ZKERDYbF4MRYHbHzGR2x8zumAFtimPqLyUVjPU</addsrcrecordid><sourcetype>Index Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>The doxorubicin-streptozotocin combination for the treatment of advanced well-differentiated pancreatic endocrine carcinoma: a judicious option?</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Delaunoit, Th ; Ducreux, M. ; Boige, V. ; Dromain, C. ; Sabourin, J.-C. ; Duvillard, P. ; Schlumberger, M. ; de Baere, T. ; Rougier, P. ; Ruffie, P. ; Elias, D. ; Lasser, P. ; Baudin, E.</creator><creatorcontrib>Delaunoit, Th ; Ducreux, M. ; Boige, V. ; Dromain, C. ; Sabourin, J.-C. ; Duvillard, P. ; Schlumberger, M. ; de Baere, T. ; Rougier, P. ; Ruffie, P. ; Elias, D. ; Lasser, P. ; Baudin, E.</creatorcontrib><description>Due to their rarity, only few trials have studied the role of the doxorubicin-streptozotocin (DS) combination in advanced well-differentiated pancreatic endocrine carcinomas (AWDPEC). However, the published results are inconsistent. We reviewed all AWDPEC (5-year period, 45 patients) treated in our institution with the DS combination for: objective response rate (ORR), progression-free survival, overall survival (OS) and toxicity. An ORR of 36% (95% Confidence Interval (CI) 22–49) was obtained, with 16 partial responses (PR). The mean duration of PR was of 19.7 months. Two and 3-year OS rates were 50.2 and 24.4%, respectively. Toxicities were mainly digestive (grade ⩾3 vomiting, 13%) and haematological (grade ⩾3 neutropenia, 24%). Previous systemic chemotherapy and malignant hepatomegaly were associated with a poorer ORR (P=0.033, P=0.016) and OS (P=0.008, P=0.045). Multivariate analysis demonstrated previous chemotherapy as the only independent predictive-factor for survival (P=0.013). In conclusion, our data confirm the sensitivity of AWDPEC to the DS combination, with an ORR of 36% and a remarkable median response duration of 19.7 months, and suggests that it could be considered as a valid option in first-line therapy.</description><identifier>ISSN: 0959-8049</identifier><identifier>EISSN: 1879-0852</identifier><identifier>DOI: 10.1016/j.ejca.2003.09.035</identifier><identifier>PMID: 14962717</identifier><language>eng</language><publisher>Oxford: Elsevier Ltd</publisher><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Biological and medical sciences ; Chemotherapy ; Doxorubicin - administration & dosage ; Doxorubicin - adverse effects ; Female ; Follow-Up Studies ; Humans ; Male ; Medical sciences ; Middle Aged ; Neuroendocrine carcinoma ; Pancreas ; Pancreatic Neoplasms - drug therapy ; Pharmacology. Drug treatments ; Streptozocin - administration & dosage ; Streptozocin - adverse effects ; Survival Analysis ; Treatment Outcome ; Tumors</subject><ispartof>European journal of cancer (1990), 2004-03, Vol.40 (4), p.515-520</ispartof><rights>2003 Elsevier Science Ltd</rights><rights>2004 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0959804903009274$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=15484007$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/14962717$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Delaunoit, Th</creatorcontrib><creatorcontrib>Ducreux, M.</creatorcontrib><creatorcontrib>Boige, V.</creatorcontrib><creatorcontrib>Dromain, C.</creatorcontrib><creatorcontrib>Sabourin, J.-C.</creatorcontrib><creatorcontrib>Duvillard, P.</creatorcontrib><creatorcontrib>Schlumberger, M.</creatorcontrib><creatorcontrib>de Baere, T.</creatorcontrib><creatorcontrib>Rougier, P.</creatorcontrib><creatorcontrib>Ruffie, P.</creatorcontrib><creatorcontrib>Elias, D.</creatorcontrib><creatorcontrib>Lasser, P.</creatorcontrib><creatorcontrib>Baudin, E.</creatorcontrib><title>The doxorubicin-streptozotocin combination for the treatment of advanced well-differentiated pancreatic endocrine carcinoma: a judicious option?</title><title>European journal of cancer (1990)</title><addtitle>Eur J Cancer</addtitle><description>Due to their rarity, only few trials have studied the role of the doxorubicin-streptozotocin (DS) combination in advanced well-differentiated pancreatic endocrine carcinomas (AWDPEC). However, the published results are inconsistent. We reviewed all AWDPEC (5-year period, 45 patients) treated in our institution with the DS combination for: objective response rate (ORR), progression-free survival, overall survival (OS) and toxicity. An ORR of 36% (95% Confidence Interval (CI) 22–49) was obtained, with 16 partial responses (PR). The mean duration of PR was of 19.7 months. Two and 3-year OS rates were 50.2 and 24.4%, respectively. Toxicities were mainly digestive (grade ⩾3 vomiting, 13%) and haematological (grade ⩾3 neutropenia, 24%). Previous systemic chemotherapy and malignant hepatomegaly were associated with a poorer ORR (P=0.033, P=0.016) and OS (P=0.008, P=0.045). Multivariate analysis demonstrated previous chemotherapy as the only independent predictive-factor for survival (P=0.013). In conclusion, our data confirm the sensitivity of AWDPEC to the DS combination, with an ORR of 36% and a remarkable median response duration of 19.7 months, and suggests that it could be considered as a valid option in first-line therapy.</description><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Chemotherapy</subject><subject>Doxorubicin - administration & dosage</subject><subject>Doxorubicin - adverse effects</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Humans</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Neuroendocrine carcinoma</subject><subject>Pancreas</subject><subject>Pancreatic Neoplasms - drug therapy</subject><subject>Pharmacology. Drug treatments</subject><subject>Streptozocin - administration & dosage</subject><subject>Streptozocin - adverse effects</subject><subject>Survival Analysis</subject><subject>Treatment Outcome</subject><subject>Tumors</subject><issn>0959-8049</issn><issn>1879-0852</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFkctu1TAQhi1ERQ-FF2CBvGGZMLZzM0JCVcWlUiU2ZW1N7LFwdBJHjk9peQoeGUctYjWamU9z-X_G3gioBYju_VTTZLGWAKoGXYNqn7GDGHpdwdDK5-wAutXVAI0-Zy-3bQKAfmjgBTsXje5kL_oD-3P7k7iL9zGdxmDDUm050Zrj75hjSbmN8xgWzCEu3MfEc8ELgXmmJfPoObo7XCw5_ouOx8oF7ymVVsBcamtp7XCwnBYXbQoLcYupTI4zfuDIp5Mra-Np43Hdl3x6xc48Hjd6_RQv2I8vn2-vvlU3379eX13eVCS1zJXQHYkGPWkYOgdOKqsReulJOQ29H4TtWzl6QX4EZW0nPZBTreqRtMBOXbC3j3PX0ziTM2sKM6YH80-aArx7AnCzePSp_BK2_1zbFC1h5z4-clSuvQuUzGYD7ZKERDYbF4MRYHbHzGR2x8zumAFtimPqLyUVjPU</recordid><startdate>20040301</startdate><enddate>20040301</enddate><creator>Delaunoit, Th</creator><creator>Ducreux, M.</creator><creator>Boige, V.</creator><creator>Dromain, C.</creator><creator>Sabourin, J.-C.</creator><creator>Duvillard, P.</creator><creator>Schlumberger, M.</creator><creator>de Baere, T.</creator><creator>Rougier, P.</creator><creator>Ruffie, P.</creator><creator>Elias, D.</creator><creator>Lasser, P.</creator><creator>Baudin, E.</creator><general>Elsevier Ltd</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope></search><sort><creationdate>20040301</creationdate><title>The doxorubicin-streptozotocin combination for the treatment of advanced well-differentiated pancreatic endocrine carcinoma: a judicious option?</title><author>Delaunoit, Th ; Ducreux, M. ; Boige, V. ; Dromain, C. ; Sabourin, J.-C. ; Duvillard, P. ; Schlumberger, M. ; de Baere, T. ; Rougier, P. ; Ruffie, P. ; Elias, D. ; Lasser, P. ; Baudin, E.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-e292t-196e14afe9086d0d23c9a072fe3d907f81c752bf1efb03cc62f0ed3537ae91a63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Chemotherapy</topic><topic>Doxorubicin - administration & dosage</topic><topic>Doxorubicin - adverse effects</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Humans</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Neuroendocrine carcinoma</topic><topic>Pancreas</topic><topic>Pancreatic Neoplasms - drug therapy</topic><topic>Pharmacology. Drug treatments</topic><topic>Streptozocin - administration & dosage</topic><topic>Streptozocin - adverse effects</topic><topic>Survival Analysis</topic><topic>Treatment Outcome</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Delaunoit, Th</creatorcontrib><creatorcontrib>Ducreux, M.</creatorcontrib><creatorcontrib>Boige, V.</creatorcontrib><creatorcontrib>Dromain, C.</creatorcontrib><creatorcontrib>Sabourin, J.-C.</creatorcontrib><creatorcontrib>Duvillard, P.</creatorcontrib><creatorcontrib>Schlumberger, M.</creatorcontrib><creatorcontrib>de Baere, T.</creatorcontrib><creatorcontrib>Rougier, P.</creatorcontrib><creatorcontrib>Ruffie, P.</creatorcontrib><creatorcontrib>Elias, D.</creatorcontrib><creatorcontrib>Lasser, P.</creatorcontrib><creatorcontrib>Baudin, E.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><jtitle>European journal of cancer (1990)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Delaunoit, Th</au><au>Ducreux, M.</au><au>Boige, V.</au><au>Dromain, C.</au><au>Sabourin, J.-C.</au><au>Duvillard, P.</au><au>Schlumberger, M.</au><au>de Baere, T.</au><au>Rougier, P.</au><au>Ruffie, P.</au><au>Elias, D.</au><au>Lasser, P.</au><au>Baudin, E.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The doxorubicin-streptozotocin combination for the treatment of advanced well-differentiated pancreatic endocrine carcinoma: a judicious option?</atitle><jtitle>European journal of cancer (1990)</jtitle><addtitle>Eur J Cancer</addtitle><date>2004-03-01</date><risdate>2004</risdate><volume>40</volume><issue>4</issue><spage>515</spage><epage>520</epage><pages>515-520</pages><issn>0959-8049</issn><eissn>1879-0852</eissn><abstract>Due to their rarity, only few trials have studied the role of the doxorubicin-streptozotocin (DS) combination in advanced well-differentiated pancreatic endocrine carcinomas (AWDPEC). However, the published results are inconsistent. We reviewed all AWDPEC (5-year period, 45 patients) treated in our institution with the DS combination for: objective response rate (ORR), progression-free survival, overall survival (OS) and toxicity. An ORR of 36% (95% Confidence Interval (CI) 22–49) was obtained, with 16 partial responses (PR). The mean duration of PR was of 19.7 months. Two and 3-year OS rates were 50.2 and 24.4%, respectively. Toxicities were mainly digestive (grade ⩾3 vomiting, 13%) and haematological (grade ⩾3 neutropenia, 24%). Previous systemic chemotherapy and malignant hepatomegaly were associated with a poorer ORR (P=0.033, P=0.016) and OS (P=0.008, P=0.045). Multivariate analysis demonstrated previous chemotherapy as the only independent predictive-factor for survival (P=0.013). In conclusion, our data confirm the sensitivity of AWDPEC to the DS combination, with an ORR of 36% and a remarkable median response duration of 19.7 months, and suggests that it could be considered as a valid option in first-line therapy.</abstract><cop>Oxford</cop><pub>Elsevier Ltd</pub><pmid>14962717</pmid><doi>10.1016/j.ejca.2003.09.035</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0959-8049 |
| ispartof | European journal of cancer (1990), 2004-03, Vol.40 (4), p.515-520 |
| issn | 0959-8049 1879-0852 |
| language | eng |
| recordid | cdi_pubmed_primary_14962717 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biological and medical sciences Chemotherapy Doxorubicin - administration & dosage Doxorubicin - adverse effects Female Follow-Up Studies Humans Male Medical sciences Middle Aged Neuroendocrine carcinoma Pancreas Pancreatic Neoplasms - drug therapy Pharmacology. Drug treatments Streptozocin - administration & dosage Streptozocin - adverse effects Survival Analysis Treatment Outcome Tumors |
| title | The doxorubicin-streptozotocin combination for the treatment of advanced well-differentiated pancreatic endocrine carcinoma: a judicious option? |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-05T09%3A30%3A27IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-elsevier_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20doxorubicin-streptozotocin%20combination%20for%20the%20treatment%20of%20advanced%20well-differentiated%20pancreatic%20endocrine%20carcinoma:%20a%20judicious%20option?&rft.jtitle=European%20journal%20of%20cancer%20(1990)&rft.au=Delaunoit,%20Th&rft.date=2004-03-01&rft.volume=40&rft.issue=4&rft.spage=515&rft.epage=520&rft.pages=515-520&rft.issn=0959-8049&rft.eissn=1879-0852&rft_id=info:doi/10.1016/j.ejca.2003.09.035&rft_dat=%3Celsevier_pubme%3ES0959804903009274%3C/elsevier_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/14962717&rft_els_id=S0959804903009274&rfr_iscdi=true |